Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 

Click here to view
our current issue



 
 

Reducing Attrition Rates in Anticancer Drug Development

Attrition rates in the clinical phases of anticancer drug development are unacceptably high. Pam Barnacal interviews Jon Waterman-Smith of PRECOS about why this is and what can be done to predict the potential effi cacy/toxicity of new anticancer drugs before they enter the clinic.

Jon Waterman-Smith of PRECOS (December 2011)

    View full article    |    Back to Discovery Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | caitlin@samedanltd.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |